Trial Profile
A retrospective study to compare safety, efficacy and durability of simplification to single-tablet regimen of efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Jan 2017
Price :
$35
*
At a glance
- Drugs Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate (Primary) ; Emtricitabine/rilpivirine/tenofovir disoproxil fumarate (Primary)
- Indications HIV infections
- Focus Adverse reactions; Therapeutic Use
- 03 Jan 2017 New trial record